Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs: Implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062)

European Journal of Cancer

Volumn 39, Issue 13, 2003, Pages 1957-1966

  Hori, K ^a   Saito, S ^a   Sato, Y ^a   Akita, H ^a   Kawaguchi, T ^b   Sugiyama, K ^c   Sato, H ^d  

^a TOHOKU UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c Sendai Shakaihoken Hospital   (Japan)

^d Division of Internal Medicine   (Japan)

Author keywords

Antitumour; AVE8062; Combretastatin A 4; Microcirculation; Tumour blood flow; Tumour vessel

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 DERIVATIVE; CYTOTOXIC AGENT; DOXORUBICIN; FLUORESCENT DYE; MITOMYCIN C; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; UNCLASSIFIED DRUG; BIBENZYL DERIVATIVE; COMBRETASTATIN; MITOMYCIN; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG SCREENING; FLUORESCENCE; LUNG CARCINOMA; MALE; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; BLOOD FLOW VELOCITY; CANCER TRANSPLANTATION; CELL DIVISION; DRUG EFFECT; EVALUATION; LUNG TUMOR; PATHOLOGY; TREATMENT OUTCOME; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIBENZYLS; BLOOD FLOW VELOCITY; CELL DIVISION; DOXORUBICIN; LUNG NEOPLASMS; MALE; MICROCIRCULATION; MITOMYCIN; NEOPLASM TRANSPLANTATION; RATS; STILBENES; TREATMENT OUTCOME;

EID: 0142121501     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(03)00429-5     Document Type: Article

References (30)

1. Pettit G.R., Singh S.B., Hamel E., Lin C.M., Alberts D.S., Garcia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 45:1989;209-211.
2. Nihei Y., Suzuki M., Okano A.et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn. J. Cancer Res. 90:1999;1387-1395.
3. Hori K., Saito S., Nihei Y., Suzuki M., Sato Y. Antitumor effects due to irreversible stoppage of tumor tissue blood flow. evaluation of a novel combretastatin A-4 derivative, AC7700 Jpn. J. Cancer Res. 90:1999;1026-1038.
4. Nihei Y., Suga Y., Morinaga Y.et al. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn. J. Cancer Res. 90:1999;1016-1025.
5. Hori K., Saito S., Sato Y., Kubota K. Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Med. Sci. Monit. 7:2001;26-33.
6. Hori K., Saito S., Kubota K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. Br. J. Cancer. 86:2002;1604-1614.
7. Ohno T., Kawano K., Sasaki A.et al. Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer. Int. J. Clin. Oncol. 7:2002;171-176.
8. Hori K., Suzuki M., Tanda S., Saito S. In vivo analysis of tumor vascularization in the rat. Jpn. J. Cancer Res. 81:1990;279-288.
9. Shimosato Y., Watanabe K. Enzymorphological observation on irradiated tumor, with a particular reference to acid hydrolase activity. I. Light microscopic study. Gann. 58:1967;541-550.
10. Hori K., Zhang Q.-H., Li H.-.C., Saito S. Variation of growth rate of a rat tumour during a light-dark cycle. correlation with circadian fluctuations in tumour blood flow Br. J. Cancer. 71:1995;1163-1168.
11. Ohsumi K., Nakagawa R., Fukuda Y.et al. Novel combretastatin analogues effective against murine solid tumors. design and structure-activity relationships J. Med. Chem. 41:1998;3022-3032.
12. Hatanaka T., Fujita K., Ohsumi K.et al. Novel B-ring modified combretastatin analogues. syntheses and antineoplastic activity Bioorg. Med. Chem. Lett. 8:1998;3371-3374.
13. Hori K., Suzuki M., Tanda S., Saito S., Shinozaki M., Zhang Q.-H. Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension. Jpn. J. Cancer Res. 82:1991;1309-1316.
14. Gullino P.M., Grantham F.H. Studies on the exchange of fluids between host and tumor. I. A method for growing 'tissue-isolated' tumors in laboratory animals. J. Natl. Cancer Inst. 27:1961;679-693.
15. Peterson H.-I. Tumor blood flow compared with normal tissue blood flow. Peterson H.-I. Tumor Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental and Human Tumors. 1979;103-114 Boca Raton, Florida, CRC Press.
16. Hori K., Suzuki M., Tanda S., Saito S. Characterization of heterogeneous distribution of tumor blood flow in the rat. Jpn. J. Cancer Res. 82:1991;109-117.
17. Aukland K., Bower B.F., Berliner R.W. Measurement of local blood flow with hydrogen gas. Circ. Res. 14:1964;164-187.
18. Hori K., Suzuki M., Tanda S., Saito S., Shinozaki M., Zhang Q.-H. Circadian variation of tumor blood flow in rat subcutaneous tumors and its alteration by angiotensin II-induced hypertension. Cancer Res. 52:1992;912-916.
19. Paskins-Hurlburt A.J., Hollenberg N.K., Abrams H.L. Tumor perfusion in relation to the rapid growth phase and necrosis. studies on the Walker carcinoma in the rat testicle Microvasc. Res. 24:1982;15-24.
20. Yamaura H., Sato H. Quantitative studies on the developing vascular system of rat hepatoma. J. Natl. Cancer Inst. 53:1974;1229-1240.
21. Hori K., Suzuki M., Abe I., Saito S., Sato H. Increased tumor tissue pressure in association with the growth of rat tumors. Jpn. J. Cancer Res. 77:1986;65-73.
22. Wiig H., Tveit E., Hultborn R., Reed R.K., Weiss L. Interstitial fluid pressure in DMBA-induced rat mammary tumors. Scand. J. Clin. Lab. Invest. 42:1982;159-164.
23. Jain R.K. Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6:1987;559-593.
24. Hori K., Zhang Q.-H., Li H.-C., Saito S., Sato Y. Timing of cancer chemotherapy based on circadian variations in tumor tissue blood flow. Int. J. Cancer. 65:1996;360-364.
25. Rubin P., Casarett G. Microcirculation of tumors. II. The supervascularized state of irradiated regressing tumors. Clin. Radiol. 17:1966;346-355.
26. Sato K. Histological analysis of chemotherapeutic effects in cancer patients treated with angiotensin-induced hypertension chemotherapy. Kosankinbyo Kenkyusho Zasshi. 35:1983;145-155. (in Japanese).
27. Sato H., Sugiyama K., Hoshi M., Urushiyama M., Ishizuka K. Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer. with reference to resection after down staging World J. Surg. 19:1995;836-842.
28. Gee M.S., Saunders H.M., Lee J.C.et al. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res. 61:2001;2974-2982.
29. Pahernik S., Griebel J., Botzlar A.et al. Quantitative imaging of tumour blood flow by contrast-enhanced magnetic resonance imaging. Br. J. Cancer. 85:2001;1655-1663.
30. Pahernik S., Harris A.G., Schmitt-Sody M.et al. Orthogonal polarization spectral imaging as a new tool for the assessment of antivascular tumour treatment in vivo. a validation study Br. J. Cancer. 86:2002;1622-1627.